Researchers at the University of Michigan have reported promising preclinical results from an experimental approach designed to disrupt the molecular machinery that helps prostate cancer grow. The strategy, known as domain-alteration chimeras or DALTACs, uses a specially designed molecule to bring two cancer-associated proteins together in an abnormal arrangement, leaving the resulting complex unable to function normally. The findings were published in Nature on November 11, 2026. The University of Michigan’s research announcement provides details of the work.

How the experimental approach works
The researchers focused on the androgen receptor, commonly abbreviated AR, and a helper protein called p300. These proteins work together to activate genes that support the growth of many prostate cancers. Rather than simply blocking each protein separately, DALTAC-1 connects them through a carefully designed molecular structure, forcing an unnatural interaction that interferes with their normal activity. The peer-reviewed Nature paper describes the mechanism in detail.
In laboratory experiments, the molecule suppressed cancer-cell growth more effectively than the combination of inhibitors directed at the two proteins individually. The research team also reported activity in models of prostate cancer that had developed resistance to standard treatments. The findings suggest that changing how cancer-driving proteins interact may provide a new route for drug development. Medical Xpress’s report, based on the University of Michigan research, summarises the experimental results.
Results in animal models
The team evaluated the approach using prostate cancer cell lines, three-dimensional organoids derived from human cells and animal models. In the animal experiments, DALTAC-1 produced durable tumour responses, including in models resistant to existing therapies. Researchers also reported selectivity for cancer cells that depended on the AR–p300 interaction, an important consideration when attempting to limit damage to healthy tissue. The Nature study contains the experimental data and methods.
One of the notable features of the work is the proposed mechanism: instead of destroying the proteins, the molecule changes their interaction and leaves the resulting complex in a non-productive state. The authors say the approach may be useful beyond prostate cancer, although that possibility will require separate investigation for each disease and molecular target. University of Michigan researchers explain the broader potential.
Why patients should not mistake this for an available treatment
The results are encouraging, but DALTAC-1 remains at the preclinical research stage. It has not been established as a safe or effective treatment for people, and the researchers say they are working to identify a drug candidate suitable for human clinical trials. Patients should not stop, delay or replace prescribed prostate cancer treatment because of this experimental finding. The research report explicitly notes that further development is needed before human testing.
HeadlinesXtra Discovery: The research illustrates how scientists are moving beyond conventional drug strategies by attempting to reprogramme the interactions between proteins that drive cancer. Its next major test will be whether the laboratory and animal results can be translated into a safe, effective medicine for patients.